Novel anti-CGRP mAb therapies have exhibited notable proportions of responders and impressive efficacy-to-tolerability ratios in migraine patients, marking a significant advancement beyond conventional standards of care [19,20,21]. This evidence concerns the gene CALCA and migraine disorder.